EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Antigen presentation requirements for effective cDC1-based cancer immunotherapy

Josué E Pineda iD, Tomoyuki Minowa, Li Shen, Yifan Zhou, Allison Dyevoich, Bhakti Patel iD, Sarah M Schneider, Sunita Keshari, Akata Saha, Morgan N Riba, Jing Wang, Stephanie S Watowich iD und 1 weitere

The Journal of Immunology · 04.08.2026 · 215 (8)

DOI: 10.1093/jimmun/vkag198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 13.08.2026. Verfasst von Josué E Pineda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Hauptthemen laut MEDLINE: Dendritic Cells, Antigen Presentation, Cancer Vaccines, Immunotherapy. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Andrew Sabin Family Foundation Fellowship, Ruth L. Kirschstein Fellow.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 conventional dendritic cells (cDC1s) are important for generating and sustaining antitumor immunity. Accordingly, the abundance of cDC1s in human tumors correlates with improved outcomes in cancer. Capitalizing on this role, we previously demonstrated that vaccination with murine cDC1s, generated in culture from bone marrow cells (termed here “in vitro–derived cDC1s”), elicits durable tumor control in multiple preclinical models; however, the immunological mechanisms underlying the efficacy of cDC1 vaccination remain unclear. Here, we examined whether in vitro–derived cDC1s resemble tumor-infiltrating DC populations and whether MHC-I and MHC-II antigen presentation contribute to cDC1-mediated tumor control following vaccination in melanoma. As expected, MHC-I or MHC-II deficiency had minimal impact on the transcriptional state of cDC1s in homeostasis or following stimulation with the adjuvant poly dI:dC. Moreover, in vitro–derived cDC1s cultured under steady-state conditions closely resembled tumor-infiltrating cDC1s, whereas their poly dI:dC–stimulated counterparts resembled CCR7+ tumor-infiltrating DC populations, also referred to as mregDCs or LAMP3+ DCs. Our data further show that both MHC-I and MHC-II contribute to tumor control upon cDC1 vaccination and that coexpression of MHC-I and MHC-II on the same cDC1 is necessary for a robust vaccine response. We also identified an important function for host cDC1s in supporting the efficacy of vaccination with in vitro–derived cDC1s, as judged by impaired tumor control in Irf8 + 32−/− mice, which lack endogenous cDC1s. Overall, these results indicate that effective antitumor responses depend on MHC-I and MHC-II antigen presentation by vaccine-delivered cDC1s, with additional contributions from host cDC1s.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsAntigen PresentationCancer VaccinesImmunotherapyMelanoma, ExperimentalAnimalsMiceHistocompatibility Antigens Class IIMice, Inbred C57BLHistocompatibility Antigens Class IMice, KnockoutAntigens, NeoplasmCell Line, TumorFemale

Stichwörter der Autor:innen

MHC class IMHC class IIantigen presentationcancer vaccinesdendritic cells

Substanzen

Cancer VaccinesHistocompatibility Antigens Class IIHistocompatibility Antigens Class IAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • MD Anderson UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Department of Bioinformatics and Computational Biology, Division of Discovery Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

ORCID-Profile: Josué E Pineda, Bhakti Patel, Stephanie S Watowich, Matthew M Gubin

Förderung

  • NCI NIH HHS
  • Andrew Sabin Family Foundation Fellowship
  • Ruth L. Kirschstein Fellow
  • University of Texas MD Anderson Cancer Center Support Grant
  • NIAID NIH HHS
  • Graduate Scholar in the CPRIT Training
  • International Balzan Prize Foundation
  • NCI

Zitieren

APA

Pineda, J. E., Minowa, T., Shen, L., Zhou, Y., Dyevoich, A., Patel, B., Schneider, S. M., Keshari, S., Saha, A., Riba, M. N., Wang, J., Watowich, S. S., & Gubin, M. M. (2026). Antigen presentation requirements for effective cDC1-based cancer immunotherapy. The Journal of Immunology, 215(8). https://doi.org/10.1093/jimmun/vkag198

Vancouver

Pineda JE, Minowa T, Shen L, Zhou Y, Dyevoich A, Patel B, et al. Antigen presentation requirements for effective cDC1-based cancer immunotherapy. The Journal of Immunology. 2026;215(8). doi:10.1093/jimmun/vkag198

BibTeX
@article{Pineda2026,
  author = {Pineda, Josué E and Minowa, Tomoyuki and Shen, Li and Zhou, Yifan and Dyevoich, Allison and Patel, Bhakti and Schneider, Sarah M and Keshari, Sunita and Saha, Akata and Riba, Morgan N and Wang, Jing and Watowich, Stephanie S and Gubin, Matthew M},
  title = {Antigen presentation requirements for effective cDC1-based cancer immunotherapy},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {8},
  doi = {10.1093/jimmun/vkag198}
}
Kostenlos starten →